Cameron Turtle, M.B.B.S., Ph.D., F.R.A.C.P., F.R.C.P.A.
Cameron Turtle, M.B.B.S., Ph.D., F.R.A.C.P., F.R.C.P.A.
Associate Member
Clinical Research Division, Fred Hutch
Anderson Family Endowed Chair for Immunotherapy
Fred Hutch
Dr. Cameron Turtle studies how immune T cells can be engineered to fight hematologic malignancies, such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia and acute myeloid leukemia. He is an Associate Member at Fred Hutch and Associate Professor in the Department of Medicine at the University of Washington (UW) in Seattle, WA. He serves as an attending physician on the Hematopoietic Cell Transplant Service and the Immunotherapy Service at Seattle Cancer Care Alliance, Fred Hutch’s clinical care partner, and the UW Medical Center. His laboratory in the Clinical Research Division at Fred Hutch is focused on understanding the characteristics of distinct subsets of human CD8+ T cells, their potential utility for tumor immunotherapy, and their role in immune reconstitution after blood stem cell transplantation.
Dr. Turtle’s lab has extensive expertise in the genetic modification and analysis of T cells, and he leads several investigator-initiated clinical trials of CD19-targeted chimeric antigen receptor (CAR)-modified T-cell therapies for patients with B-cell malignancies.
Other Appointments & Affiliations
Associate Professor
University of Washington School of Medicine
Attending Physician
Seattle Cancer Care Alliance
Education
M.B.B.S. (Medicine), University of Sydney, Australia; 1993
Fellow of the Royal Australasian College of Physicians (FRACP); 2000
Fellow of the Royal College of Pathologists of Australasia (FRCPA); 2000
Ph.D., University of Queensland, Australia; 2005
Research Interests
Dr. Turtle’s lab takes a bench-to-bedside-to-bench approach to developing cellular immunotherapies for patients with hematologic malignancies. By studying the reasons for success and failure of T cell therapies in patients treated on their clinical trials, the team takes a rational approach to improving treatment of patients with cancer.
Active Clinical Trials
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Study Number: 9457
Phase: I
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Study Number: 9364
Phase: I
“Immune effector cell therapy has the potential to create new paradigms for the treatment of people with cancer.”
—Dr. Cameron Turtle
Dr. Turtle in the News
For the Media
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email media@fredhutch.org or call 206.667.2210